Abstract
The vast majority of malignancies detected in renal parenchyma are diagnosed as renal cell carcinoma (RCC), whose subtype discrimination and determination of prognosis may contribute to the selection of the adequate therapy. Recently, a new class of small non-coding RNAs, known as microRNAs, has proven to be among the most promising biomarkers for providing this information. Herein, we sought to add up to this knowledge by evaluating the expression levels of microRNA-145 (miR-145) in RCC. For that purpose, total RNA from 58 cancerous and 44 adjacent non-cancerous renal tissues was firstly extracted and then polyadenylated and reverse transcribed to cDNA. MiR-145 levels were finally analyzed by developing and applying a highly sensitive real-time PCR protocol, while their clinical significance was determined via comprehensive statistical analysis. Our data showed that miR-145 was significantly downregulated in cancerous samples and could discriminate between clear cell and non-clear cell subtypes. Moreover, miR-145 expression was found to be correlated with primary tumor staging of cancerous samples, something also noticed in the clear cell RCC subset, in which miR-145 levels were negatively correlated with tumor size as well. Overall, these results indicate that miR-145 might constitute a promising molecular marker for RCC classification and staging.
References
Brookman-May, S.D., May, M., Wolff, I., Zigeuner, R., Hutterer, G.C., Cindolo, L., Schips, L., De Cobelli, O., Rocco, B., De Nunzio, C., et al. (2015). Evaluation of the prognostic significance of perirenal fat invasion and tumor size in patients with pT1-pT3a localized renal cell carcinoma in a comprehensive multicenter study of the CORONA project. Can we improve prognostic discrimination for patients with stage pT3a tumors? Eur. Urol. 67, 943–951.10.1016/j.eururo.2014.11.055Search in Google Scholar PubMed
Chen, Y., Sun, Y., Rao, Q., Xu, H., Li, L., and Chang, C. (2015). Androgen receptor (AR) suppresses miRNA-145 to promote renal cell carcinoma (RCC) progression independent of VHL status. Oncotarget 6, 31203–31215.10.18632/oncotarget.4522Search in Google Scholar PubMed PubMed Central
Cui, S.Y., Wang, R., and Chen, L.B. (2014). MicroRNA-145: a potent tumour suppressor that regulates multiple cellular pathways. J. Cell Mol. Med. 18, 1913–1926.10.1111/jcmm.12358Search in Google Scholar PubMed PubMed Central
Doberstein, K., Steinmeyer, N., Hartmetz, A.K., Eberhardt, W., Mittelbronn, M., Harter, P.N., Juengel, E., Blaheta, R., Pfeilschifter, J., and Gutwein, P. (2013). MicroRNA-145 targets the metalloprotease ADAM17 and is suppressed in renal cell carcinoma patients. Neoplasia 15, 218–230.10.1593/neo.121222Search in Google Scholar PubMed PubMed Central
Eble, J.N., Sauter, G., Epstein, J.I., and Sesterhenn, I.A. (2004). World Health Organization classification of tumours. Pathology and genetics of tumours of the urinary system and male genital organs (Lyon, France: IARC Press).Search in Google Scholar
Escudier, B., Porta, C., Schmidinger, M., Algaba, F., Patard, J.J., Khoo, V., Eisen, T., and Horwich, A.; ESMO Guidelines Working Group. (2014). Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 25 (Suppl 3), iii49–iii56.10.1093/annonc/mdu259Search in Google Scholar PubMed
Faragalla, H., Youssef, Y.M., Scorilas, A., Khalil, B., White, N.M., Mejia-Guerrero, S., Khella, H., Jewett, M.A., Evans, A., Lichner, Z., et al. (2012). The clinical utility of miR-21 as a diagnostic and prognostic marker for renal cell carcinoma. J. Mol. Diagn. 14, 385–392.10.1016/j.jmoldx.2012.02.003Search in Google Scholar PubMed
Ferlay, J., Steliarova-Foucher, E., Lortet-Tieulent, J., Rosso, S., Coebergh, J.W., Comber, H., Forman, D., and Bray, F. (2013). Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur. J. Cancer 49, 1374–1403.10.1016/j.ejca.2012.12.027Search in Google Scholar PubMed
Fuhrman, S.A., Lasky, L.C., and Limas, C. (1982). Prognostic significance of morphologic parameters in renal cell carcinoma. Am. J. Surg. Pathol. 6, 655–663.10.1097/00000478-198210000-00007Search in Google Scholar PubMed
Gan, B., Lim, C., Chu, G., Hua, S., Ding, Z., Collins, M., Hu, J., Jiang, S., Fletcher-Sananikone, E., Zhuang, L., et al. (2010). FoxOs enforce a progression checkpoint to constrain mTORC1-activated renal tumorigenesis. Cancer Cell 18, 472–484.10.1016/j.ccr.2010.10.019Search in Google Scholar PubMed PubMed Central
Ha, M. and Kim, V.N. (2014). Regulation of microRNA biogenesis. Nat. Rev. Mol. Cell Biol. 15, 509–524.10.1038/nrm3838Search in Google Scholar PubMed
Hanley, J.A. and McNeil, B.J. (1982). The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143, 29–36.10.1148/radiology.143.1.7063747Search in Google Scholar PubMed
Hayes, J., Peruzzi, P.P., and Lawler, S. (2014). MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol. Med. 20, 460–449.10.1016/j.molmed.2014.06.005Search in Google Scholar PubMed
Jonas, S. and Izaurralde, E. (2015). Towards a molecular understanding of microRNA-mediated gene silencing. Nat. Rev. Genet. 16, 421–433.10.1038/nrg3965Search in Google Scholar PubMed
Jonckheere, A.R. (1954). A distribution-free k-sample test against ordered alternatives. Biometrika 41, 133–145.10.1093/biomet/41.1-2.133Search in Google Scholar
Juan, D., Alexe, G., Antes, T., Liu, H., Madabhushi, A., Delisi, C., Ganesan, S., Bhanot, G., and Liou, L.S. (2010). Identification of a microRNA panel for clear-cell kidney cancer. Urology 75, 835–841.10.1016/j.urology.2009.10.033Search in Google Scholar PubMed
Khella, H.W., Bakhet, M., Allo, G., Jewett, M.A., Girgis, A.H., Latif, A., Girgis, H., Von Both, I., Bjarnason, G.A., and Yousef, G.M. (2013). miR-192, miR-194 and miR-215: a convergent microRNA network suppressing tumor progression in renal cell carcinoma. Carcinogenesis 34, 2231–2239.10.1093/carcin/bgt184Search in Google Scholar PubMed
Khella, H.W., Butz, H., Ding, Q., Rotondo, F., Evans, K.R., Kupchak, P., Dharsee, M., Latif, A., Pasic, M.D., Lianidou, E., et al. (2015). miR-221/222 are involved in response to sunitinib treatment in metastatic renal cell carcinoma. Mol. Ther. 23, 1748–1758.10.1038/mt.2015.129Search in Google Scholar PubMed PubMed Central
Kruskal, W. H. and Wallis, W. A. (1952). Use of ranks in one-criterion variance analysis. J. Am. Statist. Assoc. 47, 583–621.10.1080/01621459.1952.10483441Search in Google Scholar
Li, M., Wang, Y., Song, Y., Bu, R., Yin, B., Fei, X., Guo, Q., and Wu, B. (2015). MicroRNAs in renal cell carcinoma: a systematic review of clinical implications. Oncol. Rep. 33, 1571–1578.10.3892/or.2015.3799Search in Google Scholar PubMed PubMed Central
Livak, K.J. and Schmittgen, T.D. (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta DeltaC(T)) Method. Methods 25, 402–408.10.1006/meth.2001.1262Search in Google Scholar PubMed
Ljungberg, B., Bensalah, K., Bex, A., Canfield, S., Dabestani, S., Giles, R.H., Hofmann, F., Hora, M., Kuczyk, M.A., Lam, T., et al. (2015). Guidelines on Renal Cell Carcinoma. Available at: http://uroweb.org/guideline/renal-cell-carcinoma/. Accessed: July 2015.Search in Google Scholar
Lu, R., Ji, Z., Li, X., Zhai, Q., Zhao, C., Jiang, Z., Zhang, S., Nie, L., and Yu, Z. (2014). miR-145 functions as tumor suppressor and targets two oncogenes, ANGPT2 and NEDD9, in renal cell carcinoma. J. Cancer Res. Clin. Oncol. 140, 387–397.10.1007/s00432-013-1577-zSearch in Google Scholar PubMed
Mann, H.B. and Whitney, D.R. (1947). On a test of whether one of two random variables is stochastically larger than the other. Ann. Math. Stat. 18, 50–60.10.1214/aoms/1177730491Search in Google Scholar
Maroto, P. and Rini, B. (2014). Molecular biomarkers in advanced renal cell carcinoma. Clin. Cancer Res. 20, 2060–2071.10.1158/1078-0432.CCR-13-1351Search in Google Scholar PubMed
Motzer, R.J., Jonasch, E., Agarwal, N., Beard, C., Bhayani, S., Bolger, G.B., Chang, S.S., Choueiri, T.K., Costello, B.A., Derweesh, I.H., et al. (2015). Kidney cancer, version 3.2015. J. Natl. Compr. Canc. Netw. 13, 151–159.10.6004/jnccn.2015.0022Search in Google Scholar PubMed
Nakada, C., Matsuura, K., Tsukamoto, Y., Tanigawa, M., Yoshimoto, T., Narimatsu, T., Nguyen, L.T., Hijiya, N., Uchida, T., Sato, F., et al. (2008). Genome-wide microRNA expression profiling in renal cell carcinoma: significant down-regulation of miR-141 and miR-200c. J. Pathol. 216, 418–427.10.1002/path.2437Search in Google Scholar PubMed
Rioux-Leclercq, N., Karakiewicz, P.I., Trinh, Q.D., Ficarra, V., Cindolo, L., de la Taille, A., Tostain, J., Zigeuner, R., Mejean, A., and Patard, J.J. (2007). Prognostic ability of simplified nuclear grading of renal cell carcinoma. Cancer 109, 868–874.10.1002/cncr.22463Search in Google Scholar PubMed
Sachdeva, M., Zhu, S., Wu, F., Wu, H., Walia, V., Kumar, S., Elble, R., Watabe, K., and Mo, Y.Y. (2009). p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc. Natl. Acad. Sci. USA 106, 3207–3212.10.1073/pnas.0808042106Search in Google Scholar PubMed PubMed Central
Sachdeva, M., Liu, Q., Cao, J., Lu, Z., and Mo, Y.Y. (2012). Negative regulation of miR-145 by C/EBP-β through the Akt pathway in cancer cells. Nucleic Acids Res. 40, 6683–6692.10.1093/nar/gks324Search in Google Scholar PubMed PubMed Central
Shi, R. and Chiang, V.L. (2005). Facile means for quantifying microRNA expression by real-time PCR. Biotechniques 39, 519–525.10.2144/000112010Search in Google Scholar PubMed
Siegel, R.L., Miller, K.D., and Jemal, A. (2015). Cancer statistics, 2015. CA Cancer J. Clin. 65, 5–29.10.3322/caac.21254Search in Google Scholar PubMed
Slaby, O., Redova, M., Poprach, A., Nekvindova, J., Iliev, R., Radova, L., Lakomy, R., Svoboda, M., and Vyzula, R. (2012). Identification of microRNAs associated with early relapse after nephrectomy in renal cell carcinoma patients. Genes Chromosomes Cancer 51, 707–716.10.1002/gcc.21957Search in Google Scholar PubMed
Sobin, L.H., Gospodariwicz, M.K., and Wittekind, C. (2009). TNM Classification of Malignant Tumours (Hoboken, NJ, USA: Wiley-Blackwell).Search in Google Scholar
Wach, S., Nolte, E., Theil, A., Stöhr, C., T. Rau, T., Hartmann, A., Ekici, A., Keck, B., Taubert, H., and Wullich, B. (2013). MicroRNA profiles classify papillary renal cell carcinoma subtypes. Br. J. Cancer 109, 714–722.10.1038/bjc.2013.313Search in Google Scholar PubMed PubMed Central
White, N.M., Khella, H.W., Grigull, J., Adzovic, S., Youssef, Y.M., Honey, R.J., Stewart, R., Pace, K.T., Bjarnason, G.A., Jewett, M.A., et al. (2011). miRNA profiling in metastatic renal cell carcinoma reveals a tumour-suppressor effect for miR-215. Br. J. Cancer 105, 1741–1749.10.1038/bjc.2011.401Search in Google Scholar PubMed PubMed Central
Wotschofsky, Z., Liep, J., Meyer, H.A., Jung, M., Wagner, I., Disch, A.C., Schaser, K.D., Melcher, I., Kilic, E., Busch, J., et al. (2012). Identification of metastamirs as metastasis-associated microRNAs in clear cell renal cell carcinomas. Int. J. Biol. Sci. 8, 1363–1374.10.7150/ijbs.5106Search in Google Scholar PubMed PubMed Central
Wu, D., Li, M., Wang, L., Zhou, Y., Zhou, J., Pan, H., and Qu, P. (2014). MicroRNA-145 inhibits cell proliferation, migration and invasion by targeting matrix metallopeptidase-11 in renal cell carcinoma. Mol. Med. Rep. 10, 393–398.10.3892/mmr.2014.2149Search in Google Scholar PubMed
Yoshino, H., Enokida, H., Itesako, T., Kojima, S., Kinoshita, T., Tatarano, S., Chiyomaru, T., Nakagawa, M., and Seki, N. (2013). Tumor-suppressive microRNA-143/145 cluster targets hexokinase-2 in renal cell carcinoma. Cancer Sci. 104, 1567–1574.10.1111/cas.12280Search in Google Scholar PubMed PubMed Central
©2016 by De Gruyter
